Allergen immunotherapy for house dust mite: Clinical efficacy and immunological mechanisms in allergic rhinitis and asthma

Expert Opinion on Biological Therapy

Volumn 13, Issue 11, 2013, Pages 1543-1556

  Eifan, Aarif O ^a   Calderon, Moises A ^a   Durham, Stephen R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Allergy; Asthma; Dust mite; Immunotherapy; Rhinitis; Subcutaneous; Sublingual

Indexed keywords

CD4 ANTIGEN; CORTICOSTEROID; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANAPHYLAXIS; ASTHMA; DERMATOPHAGOIDES; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; IMMUNOTHERAPY; LOW DRUG DOSE; META ANALYSIS (TOPIC); MOUTH EDEMA; NONHUMAN; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SYMPTOMATOLOGY; THROAT IRRITATION; TREATMENT DURATION; TREATMENT OUTCOME; UNCONSCIOUSNESS;

ADMINISTRATION, SUBLINGUAL; ADULT; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; CHILD; DESENSITIZATION, IMMUNOLOGIC; HUMANS; INJECTIONS, SUBCUTANEOUS; META-ANALYSIS AS TOPIC; MODELS, IMMUNOLOGICAL; MULTICENTER STUDIES AS TOPIC; PREVALENCE; PYROGLYPHIDAE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC, PERENNIAL; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 84885663804     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.844226     Document Type: Review

References (80)

1. Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med 2006á355:2226-35
2. Platts-Mills T, de Weck AL, Aalberse R, et al. Dust mite allergens and asthma-A worldwide problem. J Allergy Clin Immunol 1989á83(2 Pt 1):416-27
3. Lodge CJ, Lowe AJ, Gurrin LC, et al. House dust mite sensitization in toddlers predicts current wheeze at age 12 years. J Allergy Clin Immunol 2011á128(4):782-8
4. Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: A longitudinal population-based study. Lancet 2008á372(9643):1049-57
5. Sheikh A, Hurwitz B, Nurmatov U, van Schayck CP. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev 2010(7):CD001563
6. Gøatzsche PC, Johansen HK. House dust mite control measures for asthma. Cochrane Database Syst Rev 2008(2):CD001187
7. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998á102(4 Pt 1):558-62
8. Bacharier LB, Boner A, Carlsen KH, et al. Diagnosis and treatment of asthma in childhood: A PRACTALL consensus report. Allergy 2008á63:5-34
9. Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol 2011á11(6):586-93
10. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010 4(8):CD001186
11. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007á24(1): CD001936
12. Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World allergy organization position paper 2009. World Allergy Organ J 2009á2(11):233-81
13. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010(12):CD002893
14. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: Results of a GA2LEN meta-analysis. Allergy 2009á64(11):1570-9
15. Calamita Z, Saconato H, Pelá AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: Systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006á61(10):1162- 72
16. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990á18(5):277-84
17. Hirsch T, Sadie;hn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997á8(1):21-7
18. Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998á351:629-32
19. Bousquet J, Scheinmann P, Guinnepain MT, et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: A double-blind, placebo-controlled study. Allergy 1999á55:249-60
20. Guez S, Vatrinet C, Fadel R, André C. House dust mite sublingual swallow immunotherapy (SLIT) in perennial rhinitis: A double blind, placebo-controlled study. Allergy 2000á55:369-75
21. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: A double- blind, placebo-controlled study. Allergy 2000á55:842-9
22. Bahceciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: A double-blind, placebo-controlled study. Pediatr Pulmonol 2001á32:49-55
23. Ippoliti F, De Santis W, Volterrani A, et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003á14(3):216-21
24. Tonnel AB, Scherpereel A, Douay B, et al. Allergic rhinitis due to house dust mites: Evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004á59(5):491-7
25. Marcucci F, Sensi L, Di Cara G, et al. Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy. Pediatr Allergy Immunol 2005á16(6):519-26
26. Passalacqua G, Pasquali M, Ariano R, et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy 2006á61(7):849-54
27. Niu CK, Chen WY, Huang JL, et al. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: A multi-center, double-blind, randomized, and placebo- controlled study in Taiwan. Respir Med 2006á100:1374-83
28. Lue KH, Lin YH, Sun HL, et al. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: A double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006á17:408-15
29. Pham-Thi N, Scheinmann P, Fadel R, et al. Assessment of sublingual immunotherapy efficacy in children with house dust mite induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol 2007á18:47-57
30. O'Hehir RE, Gardner LM, de Leon MP, et al. House dust mite sublingual immunotherapy: The role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med 2009á180(10):936-47
31. Yonekura S, Okamoto Y, Sakurai D, et al. Sublingual immunotherapy with house dust extract for house dust-mite allergic rhinitis in children. Allergol Int 2010 59(4):381-8
32. Bush RK, Swenson C, Fahlberg B, et al. House dust mite sublingual immunotherapy: Results of a US trial. J Allergy Clin Immunol 2011á127(4):974-81
33. de Bot CM, Moed H, Berger MY, et al. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. Pediatr Allergy Immunol 2012á23(2):150-8
34. Yukselen A, Kendirli SG, Yilmaz M, et al. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: A randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol 2012á157(3):288-98
35. Bozek A, Ignasiak B, Filipowska B, Jarzab J. House dust mite sublingual immunotherapy: A double-blind, placebo-controlled study in elderly patients with allergic rhinitis. Clin Exp Allergy 2013á43(2):242-8
36. Ameal A, Vega-Chicote JM, Fernández S, et al. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy 2005á60(9):1178-83
37. García-Robaina JC, Sánchez I, de la Torre F, et al. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol 2006á118(5):1026-32
38. Blumberga G, Groes L, Haugaard L, Dahl R. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy 2006á61(7):843-8
39. Wang H, Lin X, Hao C, et al. A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy 2006á61(2):191-7
40. Blumberga G, Groes L, Dahl R. SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma. Allergy 2011á66(2):178-85
41. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011á66(6):740-52
42. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008á63(3):374
43. Calderón MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: Mode of action and its relationship with the safety profile. Allergy 2012á67(3):302-11
44. Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy 2006á61(Suppl 82):1-20
45. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010 125:569-74
46. Winther L, Arnved J, Malling HJ, et al. Side-effects of allergen-specific immunotherapy: A prospective multi-centre study. Clin Exp Allergy 2006á36(3):254-60
47. Eifan AO, Akkoc T, Yildiz A, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: An open randomized controlled trial. Clin Exp Allergy 2010 40:922-32
48. Keles S, Karakoc-Aydiner E, Ozen A, et al. A novel approach in allergen specific immunotherapy: Combination of sublingual and subcutaneous routes. J Allergy Clin Immunol 2011á128:808-15
49. Piazza I, Bizzaro N. Humoral response to subcutaneous, oral, and nasal immunotherapy for allergic rhinitis due to Dermatophagoides pteronyssinus. Ann Allergy 1993á71(5):461-9
50. Mungan D, Misirligil Z, Gürbüz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma: A placebo controlled study. Ann Allergy Asthma Immunol 1999á82:485-90
51. Shamji MH, Ljøarring C, Francis JN, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012á67(2):217-26
52. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass pollen immunotherapy. N Engl J Med 1999á341:468-75
53. Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996á51:430-3
54. Naclerio RM, Proud D, Moylan B, et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol 1997á100:293-300
55. Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997á99(4):450-3
56. Cools M, Van Bever HP, Weyler JJ, Stevens WJ. Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen. Allergy 2000á55(1):69-73
57. Pajno GB, Barberio G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001á31(9): 1392-7
58. Tabar AI, Arroabarren E, Echechipía S, et al. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol 2011á127(1):57-63
59. Stelmach I, Sobocińska A, Majak P, et al. Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy. Ann Allergy Asthma Immunol 2012á109(4):274-8
60. Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012á129(3):717- 25
61. Di Rienzo V, Marcucci F, Puccinelli P, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: A 10-year prospective study. Clin Exp Allergy 2003á33(2):206-10
62. Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study. J Allergy Clin Immunol 2010 126(5):969-75
63. Robinson DS, Larché M, Durham SR. Tregs and allergic disease. J Clin Invest 2004á114(10):1389-97
64. Francis JN, James LK, Paraskevopoulos G, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008á121:1120-5
65. Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011á127:64-71
66. Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004á172:3252-9
67. Pilette C, Nouri-Aria KT, Jacobson MR, et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol 2007á178:4658-66
68. Meiler F, Zumkehr J, Klunker S, et al. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008á205:2887-98
69. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008á121:1467-72
70. Scadding GW, Shamji MH, Jacobson MR, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010 40:598-606
71. Dreborg S, Lee TH, Kay AB, Durham SR. Immunotherapy is allergenspecific: A double-blind trial of mite or timothy extract in mite and grass dual-allergic patients. Int Arch Allergy Immunol 2012á158(1):63-70
72. Linneberg A, Jacobsen RK, Jespersen L, Abildstrøam SZ. Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. J Allergy Clin Immunol 2012á129(2):413-19
73. Baron-Bodo V, Batard T, Nguyen H, et al. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy. Clin Exp Allergy 2012á42(10):1510-18
74. Bahceciler NN, Arikan C, Taylor A, et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005á136(3):287-94
75. Cosmi L, Santarlasci V, Angeli R, et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-g- and interleukin-10-production. Clin Exp Allergy 2006á36:261-72
76. Ciprandi G, Fenoglio D, Cirillo I, et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: A preliminary report. Ann Allergy Asthma Immunol 2005á95:38-44
77. Bohle B, Kinaciyan T, Gerstmayr M, et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007á120:707-13
78. Swamy RS, Reshamwala N, Hunter T, et al. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. J Allergy Clin Immunol 2012á130:215-24
79. Gardner LM, Thien FC, Douglass JA, et al. Induction of T 'regulatory' cells by standardized house dust mite immunotherapy: An increase in CD4+ CD25+ interleukin-10+ T cells expressing peripheral tissue trafficking markers. Clin Exp Allergy 2004á34(8):1209-19
80. Lou W, Wang C, Wang Y, et al. Responses of CD4(+) CD25(+) Foxp3(+) and IL-10-secreting type I T regulatory cells to cluster-specific immunotherapy for allergic rhinitis in children. Pediatr Allergy Immunol 2012á23(2):140-9